Cargando…

Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization

Peritoneal fibrosis contributes to ultrafiltration failure in peritoneal dialysis (PD) patients and thus restricts the wide application of PD in clinic. Recently we have demonstrated that histone deacetylase 6 (HDAC6) is critically implicated in high glucose peritoneal dialysis fluid (HG-PDF) induce...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yingfeng, Li, Jinqing, Chen, Hui, Hu, Yan, Tang, Lunxian, Zhou, Xun, Tao, Min, Lv, Zexin, Chen, Si, Qiu, Andong, Liu, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240186/
https://www.ncbi.nlm.nih.gov/pubmed/35784347
http://dx.doi.org/10.3389/fimmu.2022.899140
_version_ 1784737475236724736
author Shi, Yingfeng
Li, Jinqing
Chen, Hui
Hu, Yan
Tang, Lunxian
Zhou, Xun
Tao, Min
Lv, Zexin
Chen, Si
Qiu, Andong
Liu, Na
author_facet Shi, Yingfeng
Li, Jinqing
Chen, Hui
Hu, Yan
Tang, Lunxian
Zhou, Xun
Tao, Min
Lv, Zexin
Chen, Si
Qiu, Andong
Liu, Na
author_sort Shi, Yingfeng
collection PubMed
description Peritoneal fibrosis contributes to ultrafiltration failure in peritoneal dialysis (PD) patients and thus restricts the wide application of PD in clinic. Recently we have demonstrated that histone deacetylase 6 (HDAC6) is critically implicated in high glucose peritoneal dialysis fluid (HG-PDF) induced peritoneal fibrosis, however, the precise mechanisms of HDAC6 in peritoneal fibrosis have not been elucidated. Here, we focused on the role and mechanisms of HDAC6 in chlorhexidine gluconate (CG) induced peritoneal fibrosis and discussed the mechanisms involved. We found Tubastatin A (TA), a selective inhibitor of HDAC6, significantly prevented the progression of peritoneal fibrosis, as characterized by reduction of epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) protein deposition. Inhibition of HDAC6 remarkably suppressed the expression of matrix metalloproteinases-2 (MMP2) and MMP-9. Administration of TA also increased the expression of acetylation Histone H3 and acetylation α-tubulin. Moreover, our results revealed that blockade of HDAC6 inhibited alternatively M2 macrophages polarization by suppressing the activation of TGF-β/Smad3, PI3K/AKT, and STAT3, STAT6 pathways. To give a better understanding of the mechanisms, we further established two cell injured models in Raw264.7 cells by using IL-4 and HG-PDF. Our in vitro experiments illustrated that both IL-4 and HG-PDF could induce M2 macrophage polarization, as demonstrated by upregulation of CD163 and Arginase-1. Inhibition of HDAC6 by TA significantly abrogated M2 macrophage polarization dose-dependently by suppressing TGF-β/Smad, IL4/STAT6, and PI3K/AKT signaling pathways. Collectively, our study revealed that blockade of HDAC6 by TA could suppress the progression of CG-induced peritoneal fibrosis by blockade of M2 macrophage polarization. Thus, HDAC6 may be a promising target in peritoneal fibrosis treatment.
format Online
Article
Text
id pubmed-9240186
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92401862022-06-30 Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization Shi, Yingfeng Li, Jinqing Chen, Hui Hu, Yan Tang, Lunxian Zhou, Xun Tao, Min Lv, Zexin Chen, Si Qiu, Andong Liu, Na Front Immunol Immunology Peritoneal fibrosis contributes to ultrafiltration failure in peritoneal dialysis (PD) patients and thus restricts the wide application of PD in clinic. Recently we have demonstrated that histone deacetylase 6 (HDAC6) is critically implicated in high glucose peritoneal dialysis fluid (HG-PDF) induced peritoneal fibrosis, however, the precise mechanisms of HDAC6 in peritoneal fibrosis have not been elucidated. Here, we focused on the role and mechanisms of HDAC6 in chlorhexidine gluconate (CG) induced peritoneal fibrosis and discussed the mechanisms involved. We found Tubastatin A (TA), a selective inhibitor of HDAC6, significantly prevented the progression of peritoneal fibrosis, as characterized by reduction of epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) protein deposition. Inhibition of HDAC6 remarkably suppressed the expression of matrix metalloproteinases-2 (MMP2) and MMP-9. Administration of TA also increased the expression of acetylation Histone H3 and acetylation α-tubulin. Moreover, our results revealed that blockade of HDAC6 inhibited alternatively M2 macrophages polarization by suppressing the activation of TGF-β/Smad3, PI3K/AKT, and STAT3, STAT6 pathways. To give a better understanding of the mechanisms, we further established two cell injured models in Raw264.7 cells by using IL-4 and HG-PDF. Our in vitro experiments illustrated that both IL-4 and HG-PDF could induce M2 macrophage polarization, as demonstrated by upregulation of CD163 and Arginase-1. Inhibition of HDAC6 by TA significantly abrogated M2 macrophage polarization dose-dependently by suppressing TGF-β/Smad, IL4/STAT6, and PI3K/AKT signaling pathways. Collectively, our study revealed that blockade of HDAC6 by TA could suppress the progression of CG-induced peritoneal fibrosis by blockade of M2 macrophage polarization. Thus, HDAC6 may be a promising target in peritoneal fibrosis treatment. Frontiers Media S.A. 2022-06-15 /pmc/articles/PMC9240186/ /pubmed/35784347 http://dx.doi.org/10.3389/fimmu.2022.899140 Text en Copyright © 2022 Shi, Li, Chen, Hu, Tang, Zhou, Tao, Lv, Chen, Qiu and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Shi, Yingfeng
Li, Jinqing
Chen, Hui
Hu, Yan
Tang, Lunxian
Zhou, Xun
Tao, Min
Lv, Zexin
Chen, Si
Qiu, Andong
Liu, Na
Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization
title Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization
title_full Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization
title_fullStr Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization
title_full_unstemmed Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization
title_short Pharmacologic Inhibition of Histone Deacetylase 6 Prevents the Progression of Chlorhexidine Gluconate-Induced Peritoneal Fibrosis by Blockade of M2 Macrophage Polarization
title_sort pharmacologic inhibition of histone deacetylase 6 prevents the progression of chlorhexidine gluconate-induced peritoneal fibrosis by blockade of m2 macrophage polarization
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240186/
https://www.ncbi.nlm.nih.gov/pubmed/35784347
http://dx.doi.org/10.3389/fimmu.2022.899140
work_keys_str_mv AT shiyingfeng pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT lijinqing pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT chenhui pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT huyan pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT tanglunxian pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT zhouxun pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT taomin pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT lvzexin pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT chensi pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT qiuandong pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization
AT liuna pharmacologicinhibitionofhistonedeacetylase6preventstheprogressionofchlorhexidinegluconateinducedperitonealfibrosisbyblockadeofm2macrophagepolarization